Cargando…
Endocan: A Key Player of Cardiovascular Disease
Endothelial dysfunction is considered to be an early change in atherosclerosis. Endocan, also known as endothelial cell specific molecule-1, is a soluble proteoglycan mainly secreted by endothelial cells. Inflammatory factors such as IL-1β and TNF-α can up regulate the expression of endocan and then...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766991/ https://www.ncbi.nlm.nih.gov/pubmed/35071362 http://dx.doi.org/10.3389/fcvm.2021.798699 |
_version_ | 1784634630642597888 |
---|---|
author | Chen, Jinzhi Jiang, Liping Yu, Xiao-Hua Hu, Mi Zhang, Yang-Kai Liu, Xin He, Pingping Ouyang, Xinping |
author_facet | Chen, Jinzhi Jiang, Liping Yu, Xiao-Hua Hu, Mi Zhang, Yang-Kai Liu, Xin He, Pingping Ouyang, Xinping |
author_sort | Chen, Jinzhi |
collection | PubMed |
description | Endothelial dysfunction is considered to be an early change in atherosclerosis. Endocan, also known as endothelial cell specific molecule-1, is a soluble proteoglycan mainly secreted by endothelial cells. Inflammatory factors such as IL-1β and TNF-α can up regulate the expression of endocan and then affect the expression of cell adhesion molecules, such as ICAM-1 and VCAM-1, which play an important role in promoting leukocyte migration and inflammatory response. Elevated plasma levels of endocan may reflect endothelial activation and dysfunction, and is considered to be a potential immuno-inflammatory marker that may be related to cardiovascular disease. In the case of hypertension, diabetes, angina pectoris and acute myocardial infarction, the increase or decrease of serum endocan levels is of great significance. Here, we reviewed the current research on endocan, and emphasis its possible clinical value as a prognostic marker of cardiovascular disease. Endocan may be a useful biomarker for the prognosis of cardiovascular disease, but more research is needed on its mechanism of action. |
format | Online Article Text |
id | pubmed-8766991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87669912022-01-20 Endocan: A Key Player of Cardiovascular Disease Chen, Jinzhi Jiang, Liping Yu, Xiao-Hua Hu, Mi Zhang, Yang-Kai Liu, Xin He, Pingping Ouyang, Xinping Front Cardiovasc Med Cardiovascular Medicine Endothelial dysfunction is considered to be an early change in atherosclerosis. Endocan, also known as endothelial cell specific molecule-1, is a soluble proteoglycan mainly secreted by endothelial cells. Inflammatory factors such as IL-1β and TNF-α can up regulate the expression of endocan and then affect the expression of cell adhesion molecules, such as ICAM-1 and VCAM-1, which play an important role in promoting leukocyte migration and inflammatory response. Elevated plasma levels of endocan may reflect endothelial activation and dysfunction, and is considered to be a potential immuno-inflammatory marker that may be related to cardiovascular disease. In the case of hypertension, diabetes, angina pectoris and acute myocardial infarction, the increase or decrease of serum endocan levels is of great significance. Here, we reviewed the current research on endocan, and emphasis its possible clinical value as a prognostic marker of cardiovascular disease. Endocan may be a useful biomarker for the prognosis of cardiovascular disease, but more research is needed on its mechanism of action. Frontiers Media S.A. 2022-01-05 /pmc/articles/PMC8766991/ /pubmed/35071362 http://dx.doi.org/10.3389/fcvm.2021.798699 Text en Copyright © 2022 Chen, Jiang, Yu, Hu, Zhang, Liu, He and Ouyang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Chen, Jinzhi Jiang, Liping Yu, Xiao-Hua Hu, Mi Zhang, Yang-Kai Liu, Xin He, Pingping Ouyang, Xinping Endocan: A Key Player of Cardiovascular Disease |
title | Endocan: A Key Player of Cardiovascular Disease |
title_full | Endocan: A Key Player of Cardiovascular Disease |
title_fullStr | Endocan: A Key Player of Cardiovascular Disease |
title_full_unstemmed | Endocan: A Key Player of Cardiovascular Disease |
title_short | Endocan: A Key Player of Cardiovascular Disease |
title_sort | endocan: a key player of cardiovascular disease |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766991/ https://www.ncbi.nlm.nih.gov/pubmed/35071362 http://dx.doi.org/10.3389/fcvm.2021.798699 |
work_keys_str_mv | AT chenjinzhi endocanakeyplayerofcardiovasculardisease AT jiangliping endocanakeyplayerofcardiovasculardisease AT yuxiaohua endocanakeyplayerofcardiovasculardisease AT humi endocanakeyplayerofcardiovasculardisease AT zhangyangkai endocanakeyplayerofcardiovasculardisease AT liuxin endocanakeyplayerofcardiovasculardisease AT hepingping endocanakeyplayerofcardiovasculardisease AT ouyangxinping endocanakeyplayerofcardiovasculardisease |